Title:Collocating Novel Targets for Tuberculosis (TB) Drug Discovery
VOLUME: 18 ISSUE: 2
Author(s):Karan Gandhi and Mehul Patel*
Affiliation:Faculty of Pharmacy, Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Charusat campus, Changa, Gujarat, Department of Pharmaceutical Chemistry, Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Charusat Campus, Changa, Gujarat
Keywords:Adenosine triphosphate (ATP), amino acid, fatty acid, interferon- γ, Interleukin-10, natural resistance associated
macrophage protein 1 (NRAMP1).
Abstract:
Background: Mycobacterium tuberculosis, being a resistive species is an incessant
threat to the world population for the treatment of Tuberculosis (TB). An advanced genetic or a
molecular level approach is mandatory for both diagnosis and therapy as the prevalence of multi
drug-resistant (MDR) and extensively drug- resistant (XDR) TB.
Methods: A literature review was conducted, focusing essentially on the development of biomarkers
and targets to extrapolate the Tuberculosis Drug Discovery process.
Results and Discussion: In this article, we have discussed several substantial targets and genetic
mutations occurring in a diseased or treatment condition of TB patients. It includes expressions in
Bhlhe40, natural resistance associated macrophage protein 1 (NRAMP1) and vitamin D receptor
(VDR) with its mechanistic actions that have made a significant impact on TB. Moreover, recently
identified compounds; imidazopyridine amine derivative (Q203), biphenyl amide derivative
(DG70), azetidine, thioquinazole, tetrahydroindazole and 2- mercapto- quinazoline scaffolds for
several targets such as adenosine triphosphate (ATP), amino acid and fatty acid have been briefed
for their confirmed hits and therapeutic activity.
